



## Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

August 1, 2022

SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2022-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm Eastern Daylight Time on August 9, 2022.

### Tuesday, August 9, 2022 @ 4:30 pm EDT

Domestic: 1-800-263-0877

International: 1-323-794-2094

Conference ID: 8017918

Webcast: [Link](#)

### About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. In addition, please connect with us on Twitter and LinkedIn. For more information visit [www.ArcturusRx.com](http://www.ArcturusRx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220801005045/en/): <https://www.businesswire.com/news/home/20220801005045/en/>

### IR and Media Contacts

Arcturus Therapeutics

[IR@arcturusrx.com](mailto:IR@arcturusrx.com)

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

[ctanzi@kendallir.com](mailto:ctanzi@kendallir.com)

Source: Arcturus Therapeutics Holdings Inc.